Semaglutide vs Cagrilintide

Overview

This comparison separates Semaglutide and Cagrilintide for laboratory reference—not product selection.

Semaglutide: Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant efficacy through appetit…

Cagrilintide: Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% wei…

Key differences

• Both appear in GLP-1 & metabolic literature, but mechanistic framing differs.
• The useful distinction is research question and receptor context—not relative potency or practical ranking.

Mechanistic differences

Semaglutide: Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant effi…

Cagrilintide: Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials d…

Pharmacology

Semaglutide: Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant effi…

Cagrilintide: Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin se…

Research focus

Semaglutide: GLP-1 & metabolic: Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated signifi…

Cagrilintide: GLP-1 & metabolic: Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3…

At a glance

Practical differentiation

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/40305708/
• pubmed.ncbi.nlm.nih.gov/33567185/
• pubmed.ncbi.nlm.nih.gov/37952131/
• pubmed.ncbi.nlm.nih.gov/31185157/
• pubmed.ncbi.nlm.nih.gov/37622681/
• pubmed.ncbi.nlm.nih.gov/36322838/
• pubmed.ncbi.nlm.nih.gov/27633186/
• pubmed.ncbi.nlm.nih.gov/36216945/

FAQ